Multivariate analysis confirmed that HLA-DRB1 matching was the most significant factor influencing survival (P = 0.04), LFS (P = 0.013) and TRM We have retrospectively analyzed the impact of prognostic factors on the outcome of serologically HLA-(P = 0.0049). From these results, we have defined a 'good risk' group, ie patients transplanted in first matched unrelated donor (UD) BMT for CML. For this purpose, we have studied a cohort of 366 patients transchronic phase, from an HLA-DRB1 matched donor, without TCD as prophylaxis against GVHD. The 2 year planted in Europe between January 1985 and December 1994. The median age of the 211 males and 155 females LFS, TRM and relapse incidence for this group were 51 ± 5%, 47 ± 5% and 2 ± 2%, respectively. This sugwas 34 years; 238 patients were transplanted in first chronic phase and 116 in advanced phases. The median gests that the long-term outcome of patients with favorable prognostic features can approach that of patients interval from diagnosis to BMT was 827 days. GVHD prophylaxis consisted of CsA and MTX in 202 patients transplanted from geno-identical siblings. In contrast, the TRM for patients transplanted for advanced disease or of ex vivo or in vivo T cell depletion (TCD) in 129. Recently, DNA-based methods of HLA-class II typing from non HLA-DRB1-identical donors was 94%. Such a high TRM clearly indicates that UD BMT is not have been used to improve donor selection. We obtained complete data on 300 donor/recipient (D/R) pairs. justifiable for these individuals. Keywords: chronic myeloid leukemia; unrelated donor Among them, we have identified three groups of patients, according to specific HLA-DRB1 D/R compatibone marrow transplant bility. Two hundred and ten patients received marrow from donors identical for HLA-DRB1 (group 1). Thirtyone patients received BMT from a donor who was HLAFor patients with CML, allogeneic BMT from an HLA-DRB1 mismatched (group 2) and 59 from a donor in identical sibling is the treatment of choice. 1-4 However, whom specific HLA-DRB1 typing was not performed most patients do not have a suitable sibling donor and, for (group 3). The overall survival was 37 ± 3% at 2 years these individuals, there are a number of treatment options. and leukemia-free survival (LFS) was 31 ± 3%. In univMost are now treated with ␣-IFN, as this therapy can ariate analysis, five variables had a favorable effect on induce a major or a complete cytogenetic response in some LFS: transplant in first chronic phase (P = 0.0001), time patients 5 and improve the median survival, compared to interval from diagnosis to BMT shorter than the median those treated with hydroxyurea alone. 6,7 Nevertheless, (P = 0.01), prophylaxis of GVHD without TCD fewer than 50% of patients have a useful cytogenetic (P = 0.001), acute GVHD Ͻgrade III (P = 0.0009) and response and blast transformation is observed even in those HLA-DRB1 D/R matching (P = 0.0001). Transplantpatients who have responded. Finally, there is no evidence, related mortality (TRM) was 49 ± 4% in group 1, as yet, that this treatment can cure any patient. Similarly, 79 ± 8% in group 2 and 80 ± 6% in group 3 (P = 0.0001).
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Table 1
Clinical details of 366 patients method of GVHD prophylaxis, and a tendency to delay the transplant so that the interval from diagnosis to BMT is Median age in years (range) 34 greater than that in an equivalent cohort of sibling trans- HLA genes has now revealed a far greater degree of poly-
Status not given 12 morphism at these loci than that detected by serology. 14 sixty-six of these patients are evaluable for analysis of survival, leukemia-free survival (LFS), transplant-related mortality (TRM) and relapse incidence (RI). The patients were transplanted between January 1985 and December 1994. Analysis was conducted after February 1995, giving a Donor and recipient compatibility median follow-up of 32 months (range 2-110 months).
All donor/recipient (D/R) pairs were HLA-A, -B and -DR Patient details are provided in Table 1. matched using serological methods. The class II loci were typed either by serological methods or by more definitive Conditioning regimen DNA-based methods. The latter, ie RFLP, PCR sequencespecific oligonucleotide probing (PCR-SSOP) and PCR Of the 366 patients, 322 (88%) received TBI and chemosequence-specific priming (PCR-SSP), have varying powtherapy. The irradiation protocols differed between centers.
ers of resolution of class II specificities. 16 Recently these One hundred and fourteen (35%) patients received single methods have been used to improve donor selection. In dose (SD) irradiation and 208 (65%) patients were treated order to analyze the impact of more accurate HLA class II with various schemes of fractionated (F) TBI.
typing on the clinical outcome of transplant, we required additional information on the nature and results of the matching techniques employed for individual patients. We Prophylaxis of GVHD sent a further detailed questionnaire to all BMT centers concerned. Forty-seven centers replied, giving complete There was considerable variation between centers in the measures used to prevent GVHD. Two hundred and two data on 300 D/R pairs, who are evaluable for survival, LFS, TRM and RI. HLA-DRB1-specific alleles were identical for (55%) patients received CsA and short course MTX. 15 Fifty-eight (16%) received marrow which had been 210 D/R pairs. There were one or two HLA-DRB1 mismatches for 31 D/R pairs and specific HLA-DRB1 typing depleted of T cells ex vivo (ex vivo TCD). An additional 71 (19%) patients received in vivo T cell depletion (in vivo had not been done in 59. HLA-DQB1 alleles were identical for 164 D/R pairs, mismatched for 14 and not done in 122 TCD) with either monoclonal antibodies or anti-thymocyte globulin (ATG). Nineteen (5%) patients were treated with pairs. HLA-DPB1 alleles were identical for 36 D/R pairs, mismatched for 81, and not performed in 183 donors and CsA alone and information relating to the method of GVHD prophylaxis was unavailable for 16 patients.
their recipients.
We have identified three different groups of patients, donor gender, gender matching, TBI method, disease stage at time of transplant, time interval between diagnosis and according to the HLA-DRB1 D/R compatibility (Table 2) . Two hundred and ten patients who received marrow from BMT, method of prophylaxis of GVHD, incidence and grade of acute GVHD and graft failure and rejection. an HLA-A, -B and DRB1 identical donor were referred to as group 1 (matched group). Thirty-one patients who
In a second analysis, a sub-group of 300 patients for whom information was available concerning specific HLAreceived bone marrow from a donor who was HLA-DRB1 mismatched were referred to as group 2 (mismatched DRB1 typing was divided into three groups, ie matched, mismatched and not known. Patient-, disease-and group). Fifty-nine patients in whom specific HLA-DRB1 typing was not performed were referred to as group 3.
treatment-related variables were compared between the three cohorts using the 2 statistical method for qualitative There were no differences between the three groups of patients with respect to age, interval from diagnosis to variables. All variables recognized as possible prognostic factors or differing significantly between the three groups transplant, and the method of TBI. However, a higher proportion of patients in group 1 were transplanted in first in univariate analysis were studied using the proportional hazard model. 19 In addition to HLA-DRB1 typing, we studchronic phase than in group 2 (P = 0.03) and in group 3 (P = 0.024). There was no difference between groups 1 and ied patient age at transplant, patient gender, donor gender, year of transplant, disease status at time of transplant (first 2 with respect to the prophylaxis of GVHD. In contrast, patients in group 3 were more likely to receive in vitro or chronic phase vs all other stages), time interval between diagnosis and transplant, method of prophylaxis of GVHD in vivo T cell-depleted marrow than in group 1 (P = 0.02).
(CsA and MTX vs in vivo or ex vivo TCD) and TBI (fractionated vs single dose).
Statistical analysis
All analyses were performed using the BMDP statistical package. Leukemia-free survival (LFS) was defined as surResults vival without evidence of hematological relapse. To evaluate the probability of relapse (RI), patients dying either
All patients from the toxicity of the procedure or from any other cause not related to leukemia were censored at the time of death.
Engraftment: Engraftment was defined as the attainment of The transplant-related mortality (TRM) was defined as a peripheral blood ANC Ͼ 0.5 × 10 9 /l for 3 consecutive death while in complete remission and patients were cendays. Three hundred and thirteen patients were evaluable sored at time of relapse or last follow-up. LFS, RI, TRM for engraftment. Two hundred and seventy-nine (89%) and overall survival were estimated by the product-limit patients engrafted and 34 (11%) patients experienced method. 17 graft rejection. In the entire population of patients who received an UD BMT (n = 366), a series of characteristics were studied for a possible effect on outcome using the log rank test
Survival and leukemia-free survival: Of 366 evaluable patients, 230 have died. The overall survival was 37 ± 3% (Mantel-Cox), 18 ie patient age at transplant, patient gender, at 2 years and 35 ± 3% at 5 years. Three factors were identat 5 years. In univariate analysis, four factors had significant effects on the risk of relapse: status at transplant ified in univariate analysis which significantly affected actuarial survival (Table 3) : disease status at transplant (12 ± 3% for patients transplanted in first chronic phase and 29 ± 5% for those with more advanced disease (44 ± 3% (first chronic phase) vs 23 ± 4% (advanced phase) (P = 0.0002); time interval from diagnosis to BMT (P = 0.009)); the method of prophylaxis of GVHD (5 ± 2%, 29 ± 9% and 36 ± 8% respectively (P Ͻ 0.0001)); the grade (40 ± 4% for patients transplanted before the median of 827 days from diagnosis and 33 ± 4% for those transplanted of acute GVHD (20 ± 4%, 14 ± 5%, and 5 ± 4% respectively (P = 0.02)); and the technique of administering TBI beyond 827 days from diagnosis (P = 0.04)); and the grade of acute GVHD (respectively 49 ± 4% (grade 0-I), 41 ± 6% (8 ± 3% (SD) vs 23 ± 4% (F) (P = 0.04)). (grade II) and 13 ± 3% (grade III-IV) (P Ͻ 0.0001)).
The LFS was 33 ± 2% and 31 ± 3%, 2 years and 5 years Influence of HLA-DRB1 matching on outcome after transplant, respectively. Of the variables analyzed for their influence on LFS, four had a significant effect: disease Three hundred donor and recipient pairs were evaluable for the determination of the influence of HLA-DRB1 matching status at transplant (40 ± 3% vs 20 ± 4% (P = 0.0001)); time interval from diagnosis to BMT (38 ± 4% compared to on outcome. Patients were defined as identically matched (group 1) or mismatched (group 2) according to the criteria 28 ± 3% (P = 0.01)); the method of prophylaxis of GVHD (41 ± 3% (CsA and MTX), 28 ± 5% (in vivo TCD) and set out in the Methods section. Patients in whom HLA-DRB1 typing results were not known were defined as 20 ± 5% (ex vivo TCD) respectively (P = 0.001)); and the grade of acute GVHD (43 ± 4%, 37 ± 6% and 13 ± 3% group 3. respectively (P = 0.0009)).
Engraftment: Details of engraftment were provided for 258 of the 300 D/R pairs. Graft rejection occurred in 16 (8%) Transplant-related mortality: Death due to transplantrelated toxicity occurred in 210 patients, giving a 2 year of the 187 patients in group 1, in three of the 24 patients in group 2 (12.5%) and in 6 of the 47 (12.7%) in group probability of TRM of 61 ± 3%. Factors which significantly affected the risk of TRM in univariate analysis were: status 3 (P = NS). at transplant (55 ± 3% (in first chronic phase) vs 72 ± 5% (in advanced phase) (P = 0.002)); time interval from diagLeukemia-free survival: HLA-DRB1 matching is the most important factor influencing LFS. The 210 patients in the nosis to BMT (56 ± 4% vs 65 ± 4% (P = 0.04)); and the grade of acute GVHD (46 ± 4%, 57 ± 6% and 87 ± 3% matched group (group 1) had an LFS at 2 years of 44 ± 3% compared to 17 ± 7% for the 31 patients in the mismatched respectively (P Ͻ 0.0001)).
group (group 2) (P = 0.0004) and to 17 ± 5% for the 59 patients in group 3 (P Ͻ 0.0001) (Figure 1 ). The influence Relapse incidence: Thirty-four patients had an hematological relapse, of whom 20 have subsequently died. The actuof HLA-DQB1 and HLA-DPB1 were studied independently in the HLA-DRB1 matched group (group 1) and in arial risk of relapse was 16 ± 3% at 2 years and 20 ± 3% groups 2 and 3 ( Table 4 ). The LFS did not appear to be significantly affected by the HLA-DQ or -DP disparity. Figure 1 Kaplan-Meier probability of leukemia-free survival in patients 0-I (n = 188) 43 ± 4 20±4 49±4 46±4 who received DRB1-matched transplants (group 1) compared with those II (n = 71) 37 ± 6 14±5 41±6 57±6 who received DRB1-mismatched transplants (group 2) and with those for III-IV (n = 107) 13 ± 3 5±4 13±3 87±3 whom HLA-DRB1 typing was not done (group 3). The probability of P value 0.0009 0.02 Ͻ0.0001 Ͻ0.0001 leukemia-free survival at 2 years was 44 ± 3% for 210 DRB1-matched transplants, 17 ± 7% for 31 mismatched transplants and 17 ± 5% when DRB1 typing was not done (P Ͻ 0.0001). Significant P values are indicated in bold font. 
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Group 1 vs group 2: P = 0.0004; group 1 vs group 3: P = 0.0001.
The matched and mismatched groups were also studied dence of acute GVHD of grade II-IV in the mismatched group (23 of 31 patients) (74%) compared to the matched for the influence of other prognostic factors. Two hundred and four evaluable patients were transplanted in first group (93 of 210 patients) (44%) (P = 0.002). The TRM was also higher for the patients of group 3 (80 ± 6%) when chronic phase, 153 in group 1, 17 in group 2 and 34 in group 3. The LFS was improved if the donor was HLAcompared to group 1 (P Ͻ 0.0001). Grade II-IV acute GVHD occurred in 32 of the 59 patients (54%) (NS). DRB1 matched, being 47 ± 4% in group 1 compared to 23 ± 10% in group 2 (P = 0.014). This was largely due to a reduced TRM of 48 ± 4% for patients in group 1 comRelapse incidence: The relapse incidence was not affected by HLA-DRB1 disparity. pared to 71 ± 11% in group 2 (P = 0.013). The LFS was 29 ± 8% for the 34 patients in group 3, and the difference with group 1 was also statistically significant (P = 0.05),
Multivariate analysis: Sufficient data were available for 286 patients to be analyzed in a Cox proportional hazard with a TRM of 66 ± 9%. Similar differences between the three groups were seen for patients who were transplanted model 19 using the covariates described in the Methods section. The results are shown in Table 5 . Three factors were in advanced phases of the disease. associated with LFS and relapse risk: there was a significant reduction in relapse risk with an improved LFS for patients Transplant-related mortality: HLA-DRB1 matching was also the most important factor influencing the risk of TRM transplanted in the first chronic phase of the disease, who were conditioned with SD TBI, and received CsA and (Figure 2) . The TRM was 49 ± 4% in group 1 (matched group) and 79 ± 8% in group 2 (mismatched group) MTX as prophylaxis against GVHD. Two factors were associated with improved survival and reduced TRM: (P = 0.0002). This was largely related to an increased inciyounger age when age was analyzed as a continuous variable, and HLA compatibility. Indeed, HLA-DRB1 match- ing was the most significant factor influencing survival ber of variables which may be used to improve patient and donor selection. (P = 0.004), LFS (P = 0.013) and TRM (P = 0.0049). The outcome for patients without HLA-DRB1 typing results
We have demonstrated that the most influential factor for survival, leukemia-free survival and transplant-related was comparable to that for patients with an HLA-DRB1 mismatched donor and there was a significant difference mortality is the presence of HLA disparity. This in turn is associated with an increased risk of severe acute GVHD. when compared to HLA-DRB1 matched transplants for survival (P = 0.0012), LFS (P = 0.0028) and TRM
The selection of donors who are more precisely matched with their recipients is essential if we are to be able to (P = 0.0026).
From the results of the multivariate analysis we have reduce the incidence of GVHD-related mortality and morbidity. Due to the extreme polymorphism of certain HLA defined a 'good risk' group, ie patients transplanted in first chronic phase from a matched donor and treated with CsA loci and limited resolution of serological typing, such mismatches have not previously been exposed. However, and MTX as prophylaxis against GVHD. The survival, LFS, TRM and RI for this group are 51 ± 5%, 51 ± 5% DNA-based typing methods for HLA-DRB1 are now available 16 and we have clearly shown that identity at this locus (Figure 3 ), 47 ± 5% and 2 ± 2% respectively. In contrast, the TRM for patients transplanted for advanced disease as defined by molecular methods strongly correlates with improved outcome compared with either serological DR from an HLA-mismatched donor is 94%.
matching only or HLA-DRB1 mismatching. This suggests that these mismatches are immunogenic to allo-specific HLA-DRB1 restricted T cells.
Discussion
Despite the obvious advantages that HLA-DRB1 matching seems to offer, the actual benefits may have been under-HLA-identical sibling donors can be found for approximately 30-40% of patients with chronic myeloid leukemia. estimated in this study. This is because the exact definition of the alleles present may only be achieved by sequencing. Over the last decade, the development of numerous registries has facilitated the identification of HLA-A, -B and DNA-based techniques to identify HLA-DRB1 alleles have been developed only within the last decade and have under--DR identical volunteer unrelated donors for an additional 25-45% of patients. 20, 21 However, despite a successful outgone modifications and improvements for the relatively low resolution RFLP to higher resolution PCR-SSOP and PCRcome for some patients, UD BMT is associated with a higher incidence of complications, specifically primary or SSP. Furthermore, these latter techniques are dependent on knowledge of the sequence to optimize probe and primer secondary graft failure, severe acute GVHD, and viral infections, than HLA-identical sibling transplant. [22] [23] [24] This, design. These too have been improving as sequence information becomes available. It is likely therefore, that a together with recent publications confirming improved survival times with ␣-interferon and possibly with autologous higher proportion of HLA-DRB1 'matched' pairs are truly matched in patients typed recently than in those typed transplantation, [6] [7] [8] has made the role of UD BMT in CML increasingly difficult to define. Better selection of the earlier.
The impact of HLA-DQB1 matching on the outcome of recipient and donor, and/or improved transplant technique may reduce the incidence of post-BMT complications and UD BMT cannot be assessed accurately as so few pairs matched at HLA-DRB1 were mismatched at HLA-DQB1. result in improved clinical outcome. In this study, we have retrospectively analyzed the impact of prognostic factors Due to the proximity of the loci (100 kb) 25 and a lack of recombination between them, strong associations have on the outcome of UD BMT in a large cohort of patients transplanted for CML in Europe, and have identified a numdeveloped between HLA-DRB1 and HLA-DQB1. In practice, matching for HLA-DRB1 means matching for HLA-DQB1. Similarly those mismatched for HLA-DRB1 are likely to be mismatched for HLA-DQB1. Linkage between HLA-DRB1 and HLA-DPB1 is not evident. A high level of recombination occurs between these loci 26 and as a result, most unrelated pairs matched at HLA-A, -B and -DRB1 are mismatched at HLA-DPB1. 27, 28 However, mismatching at HLA-DPB1 did not seem to significantly affect transplant outcome in HLA-DRB1 matched pairs as has been previously reported. 29 The role of class I mismatching cannot be estimated from this study as all the evaluable patients were class I matched by serological methods. It is probable that some degree of class I mismatching would have been apparent if in all D/R pairs the testing had included isoelectric focusing (IEF). A recent publication addressing the role of assays for cytotoxic T cell precursors (CTLp) in the selection of donors CTLp and class I mismatching as determined by IEF.
30
At 2 years after transplantation, the probability of survival was 51% for Several variables which are known to influence the out-99 patients transplanted in first chronic phase from a matched donor and treated with CsA and MTX as prophylaxis against GVHD.
come of HLA-identical sibling transplants were also found to have a prognostic role of UD BMT. Older age was an irradiation (ie number of fractions, total dose, dose rate, radiation source, use of shielding etc) and will only be unfavorable risk factor for survival and transplant-related mortality. Several studies have found a significant effect resolved when the radiobiological effects of these parameters can be accurately predicted. for recipient age. 4, 24, 31 More recent studies have suggested that the adverse effect of patient age may be largely related
The method of GVHD prophylaxis influenced both leukemia-free survival and relapse risk. The increased incito HLA compatibility. In a series of 33 patients aged 50 years or older, who received transplants from HLA-identdence of acute GVHD has encouraged many investigators to employ ex vivo or in vivo T cell depletion in order to ical family members for CML in chronic phase within 1 year of diagnosis, the probability of survival at 4 years was reduce the associated morbidity and mortality. In this analysis, it has not been possible to investigate the effects of in excess of 80%. 32 In contrast, in a group of patients aged less than 18 years who underwent UD BMT for acute and different methods of ex vivo and in vivo T cell depletion, due to the small number of patients in each category, but chronic leukemias, there was no significant difference in the LFS between patients who were serologically matched it is entirely possible that the methodology itself may affect outcome. In HLA-identical sibling marrow transplants for with their donors and those who were mismatched. 33 Patients transplanted for advanced disease had signifi-CML, T cell depletion has been associated with a reduction in the incidence and severity of GVHD but at the expense cantly decreased survival, LFS and increased RI. This too confirms previously reported results for both sibling and of a higher frequency of graft failure and leukemic relapse. 38 In a series of 462 patients (of whom 196 had unrelated donor transplants. 4, 24, 31 Early transplant, ie prior to the median duration between diagnosis and BMT, con-CML), who received UD BMT facilitated by the National Marrow Donor Panel (NMDP), 70 received T cell-depleted ferred a benefit for survival, LFS and TRM in univariate, and RI in multivariate analysis. It is possible that there is grafts. They did not appear to have an increased risk of relapse when compared to patients who received unmanipua delay in proceeding to UD BMT compared to sibling transplant, partly because of the time restraints imposed by lated marrow. 34 Similarly, in a series of 48 consecutive patients who received T cell-depleted unrelated marrow at the need to identify a donor 34 and partly because of a natural reluctance on the part of patient and/or physician to a single center, the 2 year probability of relapse was low at 8.8%, suggesting an apparent preservation of graft-versusundertake a high-risk procedure. This delay may contribute to disease progression which itself has an adverse effect on leukemia activity. 39 However, in our large retrospective study, we have found that T cell depletion was an indetransplant outcome. Major cytogenetic responses to ␣-IFN are rarely seen within 9-12 months of initiation of therapy 5 pendent risk factor for relapse and was also associated with a decreased LFS in both univariate and multivariate analyand patients are understandably advised to persist with ␣-IFN for prolonged periods of time before considering UD sis. It is now possible to overcome some of the deleterious effects of T cell depletion in the sibling transplant setting BMT. However, a multivariate analysis of patients undergoing allogeneic transplants for CML has recently by the use of donor leukocyte infusions at the time of relapse. 40, 41 In the future it may be appropriate to exploit demonstrated an adverse effect of prolonged (ie Ͼ12 months) treatment with ␣-IFN. This effect was mainly the beneficial effects of T cell depletion (ie a reduced incidence and severity of acute and chronic GVHD) by adminattributable to an increased risk of graft failure and fatal infections. In this study, primary or secondary graft failure istering T cell-depleted marrow and then replacing limited numbers of lymphocytes at various time points postoccurred exclusively in patients with donors other than HLA-identical family members and was further restricted transplant. 42 In summary we have identified a number of prognostic to patients who had been previously exposed to ␣-IFN. 35 This observation requires confirmation but if correct adds variables for UD BMT for CML. Some of these (ie age, disease status and interval from diagnosis to transplant) further complexity to decisions relating to the optimal management of CML.
were expected. We have also shown the adverse effect of T cell depletion as it was performed during the years of Of the 286 patients who received TBI as part of their conditioning regimen and were evaluable in multivariate this study. More importantly we have demonstrated the importance of accurate HLA-DRB1 matching on the outanalysis, one-third received SD TBI and two-thirds were treated with fractionated TBI. Fractionated TBI has an come of transplant. Other parameters, in particular the CMV serostatus of the donor and recipient, HLA-C matchadverse influence on the relapse rate. This observation confirms that of a retrospective study from the French Registry ing 43, 44 and functional studies such as CTLp assays 30 could not be analyzed in this particular study but are likely to play which reported a significant increase in relapse incidence for patients treated with fractionated TBI compared to those a role in determining transplant outcome. In the meantime, accurate DNA-based methodology for HLA-DRB1 matchwho received SD TBI 36 but is in contrast to a number of previously published studies. In a review of the literature ing is now available and should be used to facilitate the identification of the optimal donor. Our data suggest that pertaining to TBI techniques for both acute and chronic leukemias, identical relapse rates were found for SD and the long-term outcome of patients with CML with favorable prognostic features can approach that of patients transfractionated TBI in patients who received T cell nondepleted bone marrow. 37 Similarly a report from the Interplanted from HLA-identical siblings. In contrast, the transplant-related mortality of patients transplanted in national Bone Marrow Transplant Registry did not identify fractionated TBI as a risk factor for relapse after allogeneic advanced phases of the disease from non-HLA-DRB1-identical donors is such that alternative therapies should be transplant for CML. 31 It is likely that the differences between these reports reflect the variables associated with found for these individuals.
